HighTower Advisors LLC Decreases Stake in TransMedics Group, Inc. (NASDAQ:TMDX)

HighTower Advisors LLC trimmed its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 67.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 7,682 shares of the company’s stock after selling 16,156 shares during the period. HighTower Advisors LLC’s holdings in TransMedics Group were worth $479,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Hager Investment Management Services LLC purchased a new stake in shares of TransMedics Group in the 4th quarter valued at approximately $33,000. Sachetta LLC acquired a new position in shares of TransMedics Group during the fourth quarter worth $40,000. AlphaQuest LLC purchased a new position in TransMedics Group in the fourth quarter valued at $52,000. Quarry LP increased its holdings in TransMedics Group by 557.1% in the third quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after buying an additional 312 shares during the last quarter. Finally, National Bank of Canada FI raised its stake in TransMedics Group by 174.7% in the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after buying an additional 262 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Stock Performance

Shares of TransMedics Group stock opened at $68.58 on Monday. The firm’s fifty day simple moving average is $69.11 and its 200-day simple moving average is $87.69. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37. The stock has a market capitalization of $2.31 billion, a price-to-earnings ratio of 72.96 and a beta of 2.12. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33.

Analyst Ratings Changes

Several research firms have recently issued reports on TMDX. Canaccord Genuity Group reaffirmed a “buy” rating and set a $104.00 price objective on shares of TransMedics Group in a research report on Tuesday, March 11th. Oppenheimer reiterated an “outperform” rating and issued a $125.00 price target on shares of TransMedics Group in a research note on Tuesday, December 3rd. Robert W. Baird reduced their price objective on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research report on Wednesday, December 11th. Piper Sandler lowered their target price on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a report on Wednesday, December 11th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a research note on Wednesday, March 26th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, TransMedics Group has an average rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.